Visit Website →
← Back to blog

7 FHIR Ready PGx Report Sections for Labs and Clinicians

September 30, 2026
7 FHIR Ready PGx Report Sections for Labs and Clinicians

A clinical PGx report translates a patient's genotype into a therapeutic recommendation a prescriber can act on, and it only becomes actionable when the underlying drug-gene pair carries a CPIC Level A/B rating or an FDA pharmacogenetic association. A report built for clinical use pairs a plain-language narrative with coded, structured data that a clinical decision support system can consume at the moment of prescribing.

TL;DR:

  • A PGx report is only actionable when it involves drug-gene pairs rated Level A or B by CPIC or recognized by the FDA, with clear evidence sources.
  • Preemptive panels should include copy-number variation testing for genes like CYP2D6 and a comprehensive allele list to avoid misclassification, especially for rapid or ultrarapid metabolizers.
  • Reports must link phenotype to specific medications with actionable recommendations, and include methodology details to assess the test's limitations and scope.
  • Integration into electronic health records requires structured, coded data using standards like HL7 FHIR and RxNorm to support decision support and automation.
  • Continuous reanalysis based on updated guidelines is essential, with clear protocols for tracking guideline versions and flagging outdated recommendations for review.
SignalPGx
signalpgx.com
Build FHIR Ready PGx Reports
SignalPGx helps laboratories transform genetic and medication data into physician reviewed reports with seamless HL7 and FHIR integration.
Explore SignalPGx

Table of Contents

PGx reporting overview and clinical value

Pharmacogenomic testing falls into two operational categories, and the distinction shapes everything downstream in a report. Reactive testing responds to a specific prescribing decision, typically when a patient has already had an adverse reaction or a clinician wants to confirm dosing before starting a known high-risk drug. Preemptive testing captures a multi-gene panel before a specific drug is even on the table, so the genotype data sits in the record ready for the next relevant prescription, whether that comes from oncology, psychiatry, cardiology, or a perioperative pain management plan.

CPIC and the FDA play distinct but complementary roles in making a report clinically actionable. CPIC translates genetic test results into a specific action for a specific drug, using an evidence grading system where Level A and B pairs carry recommendations strong enough to change prescribing, while CPIC guidelines intentionally stop short of telling clinicians when a test should be ordered, since that decision remains clinician-driven. The FDA maintains its own list of pharmacogenetic associations, and where CPIC and FDA labeling align, a report's recommendation carries the strongest possible clinical and regulatory footing.

The potential reach of this data is not theoretical. An EMR-based analysis of prescribing patterns found that a majority of patients in large health systems are prescribed at least one CPIC-actionable medication at some point in their care, which is the practical argument for preemptive panels: the relevant drug-gene interaction is often only one prescription away.

A clinically useful report generally needs to show:

  • The genotype-derived phenotype for each gene tested, not just raw allele calls.
  • A therapeutic implication tied to a named medication, not a generic warning.
  • The evidence source and grade behind the recommendation, whether CPIC, FDA, or both.
  • Discrete, coded data alongside the narrative so the recommendation can fire inside a CDS rule.

Anatomy of a clinical PGx report: components and what they mean

A report that mixes narrative prose with unstructured variant lists forces the clinician to do the interpretive work the report should have done already. Usability research on PGx reports found that clarity and workflow integration are the deciding factors in whether clinicians and patients act on the results, not the depth of the underlying science communicated in the report. That means every core section has a specific job.

  1. Patient and sample metadata: identifiers, specimen type, collection date, and ordering provider, which anchor the report to a specific clinical encounter.
  2. Methodology summary: the platform used, the genes and alleles tested, and whether copy-number variation was assessed, which defines the report's evidentiary boundaries.
  3. Genotype and variant observations: the raw calls at each tested locus, typically expressed with star allele nomenclature and, where relevant, rsID or HGVS notation.
  4. Diplotype and phenotype summary: the combined allele pair translated into a functional category, such as poor, intermediate, normal, rapid, or ultrarapid metabolizer.
  5. Therapeutic implication: the clinical meaning of that phenotype for a specific drug class or mechanism, written in plain language.
  6. Medication recommendation: the concrete action, whether that is a standard dose, a dose adjustment, an alternative agent, or increased monitoring.
  7. Audit trail: who reviewed the report, when, and under what version of the underlying guideline, which matters as much for compliance as for clinical trust.

The link between therapeutic implication and medication recommendation is where most reports either succeed or confuse the reader. A well-built report ties one therapeutic implication to one specific medication observation, so a clinician reading about clopidogrel response never has to guess whether a general CYP2C19 comment also applies to voriconazole dosing. Each recommendation should also state the action verb plainly: reduce dose by a stated amount, avoid, use as labeled, or consider alternative therapy.

The methodology and limitations block deserves as much attention as the recommendation itself, because it defines what the report cannot tell the reader. It should state the full allele list tested, whether CNV analysis was performed on genes like CYP2D6 where duplication and deletion alleles are common, and the detection limits of the assay. A report that omits this section leaves the clinician unable to judge whether a "normal" result reflects the patient's true genotype or simply the limits of what was tested.

Pro Tip: Before applying a recommendation, check the methodology section for CNV testing status on CYP2D6, since a missed duplication allele can turn an apparent normal metabolizer into an undetected ultrarapid one.

Nomenclature and genotype-to-phenotype translation

Star allele nomenclature is the shorthand that makes PGx reports readable across labs and specialties, and understanding it is the difference between skimming a report and actually verifying it. Each star allele designates a specific haplotype at a gene locus, so CYP2C192 and CYP2C1917 represent two different functional variants at the same gene, one reducing enzyme activity and the other increasing it. A diplotype, the pair of alleles a patient carries, such as CYP2C19 *1/*17, is what gets translated into a phenotype category.

Activity scores formalize that translation for genes like CYP2D6, where each allele is assigned a numeric value based on its functional impact, and the sum across both alleles maps to a phenotype label. A patient with an activity score of 0 is typically called a poor metabolizer, a score around 1 to 1.25 lands in the intermediate range for many gene-drug pairs, and higher scores indicate normal or ultrarapid metabolism depending on the specific scoring system in use. Ambiguous calls happen most often at score boundaries or when an allele's functional status itself is uncertain, which is why some reports flag a phenotype as "likely" rather than definitive.

Cross-referencing the underlying variant identifiers gives clinicians and pharmacists a way to verify a call independently rather than trusting the star allele translation at face value.

  • Use rsIDs to look up the specific single nucleotide variant in public variant databases when a call seems inconsistent with the patient's clinical picture.
  • Use HGVS nomenclature when a deeper look at the exact nucleotide or protein change is needed, particularly for rare or novel alleles.
  • Confirm the star allele definition table the lab used, since allele nomenclature is periodically updated and different panels may reference different versions.
  • Treat any phenotype label as conditional on the alleles actually tested, not on the full universe of alleles that could exist at that locus.

Data standards and FHIR mapping for PGx reports

A PGx report that lives only as a PDF cannot talk to an EHR's decision support engine, which is why interoperability standards matter as much as clinical accuracy. The HL7 FHIR Genomics Reporting implementation guide models a PGx report as a Genomic Report, a type of DiagnosticReport, that packages a set of Observations covering genotype, variant, and therapeutic implication data. Medication recommendations are structured as discrete tasks within that model, and each can carry a relatedArtifact link pointing to the specific CPIC or FDA guidance behind it.

That structure is not a formatting preference, it is what makes automation possible. The same implementation guide notes that limiting each TherapeuticImplication Observation to a single medication preserves the semantic link between a recommendation and its supporting genotype data, which allows a rev include search to reliably connect a recommendation back to the evidence behind it. A report that bundles multiple drugs under one implication breaks that chain and makes automated CDS firing unreliable.

A majority of patients in large health systems carry at least one CPIC-actionable prescription in their medication history, which is the practical case for building PGx data as discrete, queryable FHIR resources rather than static text.

Practical implementation guidance for labs authoring FHIR-based PGx reports includes:

  • Map medications to a standard terminology such as RxNorm so the EHR can match a genotype-based recommendation to an active or proposed prescription.
  • Structure each drug-gene recommendation as its own Observation and Task pair rather than combining several drugs into one narrative block.
  • Use relatedArtifact references to cite the specific CPIC guideline or FDA label section behind each recommendation, not a generic citation to the guideline body.
  • Confirm the EHR's ingestion pipeline actually surfaces the coded data at prescribing time, since a well-structured FHIR resource that never reaches the prescriber's screen delivers no clinical value.

Static PDF reports alone rarely change prescribing behavior, and integrating recommendations into the point-of-prescribing workflow is widely described as the primary implementation barrier labs and health systems face once the genetic data itself is accurate.

Ordering and test selection: panels, single-gene tests, and reimbursement factors

Choosing between a single-gene reactive test and a multi-gene preemptive panel depends on the clinical question in front of the ordering provider. A single-gene test fits a narrow, immediate need, such as confirming CYP2C19 status before starting clopidogrel after a stent placement, and it keeps the interpretive burden and cost contained to the question at hand. A multi-gene preemptive panel makes more sense for patients who are likely to encounter multiple PGx-relevant drugs over time, such as those starting a new psychiatric medication regimen or entering a cancer treatment pathway with several chemotherapy options on the table.

Panel content deserves scrutiny before a lab commits to a vendor or a health system commits to a panel. A clinically sound panel needs a documented allele list for each gene, explicit CNV assessment for CYP2D6 given how common duplication and deletion alleles are, and a minimum allele set broad enough to avoid misclassifying patients who carry less common but clinically significant variants.

Coverage decisions add a practical constraint on top of the clinical picture, which is why understanding BRCA gene testing coverage criteria can be informative for comparing payer policies and medical necessity processes in genetic testing. Medicare's MolDX local coverage policy states that PGx test coverage depends on demonstrated analytical validity, clinical validity, and clinical utility, and it specifically notes that combinatorial algorithms across multiple genes currently lack independent coverage support, meaning each gene in a panel needs its own justification for the clinical question being asked. Coverage decisions across payers commonly track CPIC Level A/B ratings and FDA pharmacogenetic associations as the threshold for clinical actionability, which is why documenting the specific guideline behind a test order matters for reimbursement as much as for clinical care.

Key ordering considerations to document at the time of the request:

  • The specific clinical question the test is meant to answer, not a general precision medicine goal.
  • Whether the panel's gene list matches genes with CPIC or FDA-recognized drug associations relevant to the patient's current or anticipated medications.
  • Confirmation that CNV testing is included for genes where duplication or deletion alleles are clinically significant.
  • The payer's specific coverage policy for the ordered panel, since combinatorial or bundled panels face more scrutiny than single-gene, single-purpose tests.

Interpretation pitfalls and verification: phenoconversion, panel gaps, and clinical context

A genotype does not always predict the phenotype a patient is currently experiencing, and the gap between the two is called phenoconversion. Strong CYP2D6 or CYP2C19 inhibitors, including drugs like fluoxetine and bupropion, can convert a genotypic normal metabolizer into a functional poor metabolizer for the duration of co-administration, while enzyme inducers can push a normal metabolizer toward a functional rapid metabolizer phenotype. Professional interpretation standards note that phenoconversion checks belong in the final verification step before a clinician acts on any genotype-derived recommendation, since the medication list itself can override what the genotype alone would predict.

Panel limitations create a second, quieter source of misclassification. A panel that omits an increased-function allele such as CYP2C19*17 can report a patient as a normal metabolizer when they are actually a rapid or ultrarapid metabolizer, and a panel without CNV testing on CYP2D6 can miss a gene duplication that would otherwise flag ultrarapid metabolism. Neither error shows up as a flag on the report itself, which is why the methodology section matters as much as the result.

A compact verification sequence before acting on a PGx recommendation:

  1. Confirm which alleles the panel actually tested and whether any clinically relevant alleles for the gene in question were excluded.
  2. Check whether CNV analysis was performed for genes where duplication or deletion alleles are common, particularly CYP2D6.
  3. Review the patient's active medication list for strong inhibitors or inducers of the relevant enzyme, since phenoconversion can override a genotypic call.
  4. Cross-reference the specific CPIC or FDA guidance cited in the report to confirm the recommendation matches current guidance rather than a superseded version.
  5. Document the verification step in the chart alongside the prescribing decision, particularly when the clinical decision departs from the genotypic recommendation.

Pro Tip: Treat a "normal metabolizer" call as provisional whenever the patient is also taking a known strong inhibitor or inducer of the relevant enzyme, and note the phenoconversion risk directly in the prescribing decision.

Reporting best practices for clinical laboratories

Labs building PGx reports need to think about three layers at once: the technical scope, the clinical presentation, and the operational workflow around the report's lifecycle. On the technical side, every report should disclose its allele list, CNV coverage status, and any known assay limitations directly in the report body rather than in a separate technical document that clinicians rarely see. Where relevant, the report should also carry a clear statement of laboratory accreditation status, since that context matters for how a receiving clinician or payer weighs the result.

Clinically, the strongest reports carry two layers at once: a narrative section written in plain clinical language that a prescriber can read in under a minute, and a set of discrete, coded observations underneath it that an EHR's decision support engine can act on without a human retyping the recommendation. Usability research on PGx reporting found that this dual approach, clear narrative paired with structured data, is what actually drives clinician and patient understanding, rather than either format alone.

Operationally, a few practices separate a defensible report from a liability:

  • Medical-director review of each report or report template before release, with the reviewer's identity and date recorded in an audit trail.
  • Versioning tied to the specific guideline release the recommendation reflects, so a later change in CPIC or FDA guidance can be traced against what the patient's original report said.
  • A defined reanalysis trigger, whether time-based or guideline-change-based, so a report issued years ago can be flagged for review rather than treated as permanently current.
  • A delivery workflow that distinguishes what goes to the ordering clinician, what goes to the patient portal, and what feeds directly into the EHR's structured data layer.

Pro Tip: Store the guideline version alongside each report's audit trail, not just the report date, so a future reanalysis can identify exactly which recommendations changed and why.

Patient privacy and data security considerations specific to PGx reporting

PGx data carries a distinct privacy weight compared with most lab results, because a genotype does not change over a patient's lifetime and often implies information about biological relatives who never consented to testing. Labs handling this data need to apply the same baseline protections required for any protected health information, including encryption at rest and in transit and strict access controls, but PGx reporting adds a few specific considerations on top of that baseline.

Reports should minimize the exposure of raw genotype data to systems and staff who do not need it for the clinical task at hand, since a diplotype summary and a therapeutic recommendation usually satisfy the clinical need without exposing the full variant-level dataset. Retention policies also deserve explicit thought: because PGx results remain clinically relevant indefinitely, a lab's retention and access policy needs to account for a much longer useful life than a typical lab value, while still respecting a patient's right to control how that data is stored and shared over time.

Controlled pathway for minimized PGx data sharing

Any white-label or third-party reporting infrastructure a lab relies on should carry documented compliance with the relevant regional frameworks, such as HIPAA in the United States or GDPR where it applies, and that compliance should extend to how genetic data moves between the sequencing platform, the reporting layer, and the EHR. A chain with a weak link anywhere in that path undermines the privacy protections built everywhere else.

Standardization challenges and efforts beyond FHIR/HL7, including interoperability issues

FHIR resolves how a PGx report is structured for exchange, but it does not resolve every standardization gap in the field. Star allele nomenclature itself has changed over time as new alleles are discovered and functional assignments are revised, which means two reports issued years apart on the same patient, or even the same patient tested at two different labs, can use slightly different naming conventions for the same underlying variant. That drift creates real interpretive risk when a clinician compares an old report against a new one without checking which nomenclature version each used.

Terminology harmonization efforts continue to work on aligning star allele definitions, activity score assignments, and phenotype category labels across laboratories, but adoption is uneven, and a report's methodology section remains the most reliable place to check which version of a nomenclature system was used. Coding systems for medications add another layer: a report that references a drug by brand name in the narrative but a different identifier in its coded data can create ambiguity for an EHR trying to match the recommendation to an active prescription.

Interoperability in practice also depends on whether the receiving EHR can actually parse the incoming FHIR resources correctly, since implementation guides describe an intended structure, but individual EHR vendors vary in how completely they support genomics-specific profiles. Labs and health systems both benefit from testing actual data exchange rather than assuming standards compliance on paper guarantees a working integration.

Clinical decision support integration and usage of PGx reports in electronic health records

A PGx report's clinical value depends heavily on whether its recommendation reaches the prescriber at the moment a relevant medication is being considered, not just whether the report exists somewhere in the chart. Integration into the EHR's clinical decision support engine is what makes that possible, and it works best when the underlying data is structured as discrete, coded observations rather than embedded only in narrative text.

A well-integrated system checks a patient's stored PGx data against a proposed prescription order and surfaces a specific, actionable alert, such as a dose adjustment or an alternative agent suggestion, rather than a generic warning that a genetic result exists somewhere in the record. That level of integration depends on the medication coding practices discussed earlier, since the CDS engine can only match a recommendation to a prescription order when both reference the same standard drug terminology.

The gap between having PGx data available and having it actually change prescribing behavior is well documented: integrating recommendations into the prescribing workflow itself is described as the central implementation challenge health systems face, more so than generating accurate genotype data in the first place. A static report sitting in a document repository, however accurate, delivers little clinical benefit if it never surfaces at the point where a prescribing decision is actually made.

Updating and reanalysis protocols for PGx reports as new evidence emerges

A PGx report is not a one-time document in the way a typical lab result is, because the underlying genotype data remains valid indefinitely while the clinical guidance attached to it can change as CPIC updates a guideline or the FDA revises a drug label. A report issued under one version of a guideline can become outdated in its recommendation even though the genotype itself never needs to be retested.

Labs need a defined reanalysis protocol that tracks which guideline version each issued report relied on and flags reports for review when the relevant guideline changes materially. That protocol should distinguish between a minor wording update that does not change the clinical recommendation and a substantive change, such as a new drug-gene pair reaching CPIC Level A status or an existing recommendation being reversed based on new evidence.

PGx report pathway for evidence updates

Communicating an updated recommendation back to the original ordering clinician, and ideally into the patient's active EHR record, closes the loop that a one-time report cannot. Without that mechanism, a patient's chart can carry a PGx-based recommendation that no longer reflects current guidance, and neither the clinician nor the patient has any way to know unless they happen to reorder the same test.

Implementing PGx reporting at scale: what deployment actually involves

Deploying PGx reporting infrastructure at a lab typically involves three parallel work streams: mapping the lab's existing genotype and medication data feeds, aligning the report schema with the receiving EHR's ingestion requirements, and establishing the governance around medical-director review and sign-off. Each stream tends to surface its own friction. Medication coding mismatches between the lab's internal terminology and the EHR's expected standard are common, and getting CDS alerts to fire at the correct point in the prescribing workflow, rather than too early or too late, takes iteration with the receiving health system.

Clinician uptake and privacy and compliance review round out the harder parts of a rollout, since a technically correct integration still needs the receiving clinical staff to trust and act on the recommendations it delivers. Living reanalysis, where recommendations update automatically as CPIC and FDA guidance evolves, removes a meaningful share of the long-term maintenance burden that would otherwise fall on the lab's own staff to track guideline changes manually.

— Tarek

How SignalPGx supports laboratories building clinical-grade PGx reporting

Laboratories that want the reporting practices described above without building the interpretation engine, FHIR mapping, and reanalysis workflow from scratch have a direct path through SignalPGx. The platform is built specifically for labs: it generates physician-reviewed PGx reports from genotype and medication data, maps output to HL7/FHIR for EHR integration, and runs living reanalysis so recommendations update automatically as CPIC and FDA guidance evolves.

SignalPGx

  • White-label deployment that carries your lab's own branding rather than a third-party look.
  • HL7/FHIR-native output built for direct EHR ingestion and CDS integration.
  • Living reanalysis with alerts when guideline changes affect an already-issued report.
  • Medical-director review and audit trail built into the reporting workflow.

Labs ready to see how this fits an existing sequencing and EHR setup can visit the White-Label PGx Reporting page to review deployment options, or start with Discovery & Strategy for a broader look at system design and integration needs.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

Sources

FAQ

What does "PGx" mean?

PGx is shorthand for pharmacogenomics, the study of how a person's genetic makeup affects their response to medications. A PGx report translates a patient's relevant genotypes into phenotype categories, such as poor or rapid metabolizer, tied to specific drugs.

Is PGx testing worth it?

PGx testing has the most established value for drug-gene pairs with a CPIC Level A/B rating or an FDA pharmacogenetic association, where genotype data has a documented path to changing a prescribing decision. Outside those actionable pairs, the clinical value of testing a given gene depends on the specific medication and clinical context, which is why ordering should be tied to a defined clinical question rather than broad screening.

Does insurance cover a PGx test?

Coverage depends on the payer and the specific test, and policies commonly require demonstrated analytical validity, clinical validity, and clinical utility before covering a panel. Medicare's MolDX policy specifically notes that combinatorial multi-gene algorithms currently lack independent coverage support, so each gene in a panel typically needs its own documented clinical justification.

What is the purpose of PGx testing for mental health?

In psychiatry, PGx testing most often evaluates genes like CYP2D6 and CYP2C19 that affect the metabolism of common antidepressants and antipsychotics, helping guide dose selection or drug choice when a patient has had an inadequate response or an adverse reaction. It supports the prescribing decision rather than replacing clinical judgment, and results still need to account for phenoconversion from other medications the patient is taking.